{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:58:18Z","timestamp":1792699098053,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s40265-018-0905-7","type":"journal-article","created":{"date-parts":[[2018,4,20]],"date-time":"2018-04-20T10:55:18Z","timestamp":1524221718000},"page":"707-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":108,"title":["Burosumab: First Global Approval"],"prefix":"10.1007","volume":"78","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,20]]},"reference":[{"key":"905_CR1","unstructured":"Ruppe MD. GeneReviews\u00ae: X-linked hypophosphatemia. 2017. \n                    https:\/\/www.ncbi.nlm.nih.gov\/\n                    \n                  . Accessed 6 Apr 2018."},{"key":"905_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1530\/EJE-08-0818","volume":"160","author":"SS Beck-Nielsen","year":"2009","unstructured":"Beck-Nielsen SS, Brock-Jacobsen B, Gram J, et al. Incidence and prevalence of nutritional and hereditary rickets in southern Denmark. Eur J Endocrinol. 2009;160:491\u20137.","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"905_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s00247-012-2536-6","volume":"43","author":"RM Shore","year":"2013","unstructured":"Shore RM, Chesney RW. Rickets: part II. Pediatr Radiol. 2013;43(2):152\u201372.","journal-title":"Pediatr Radiol."},{"issue":"9","key":"905_CR4","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","volume":"62","author":"I Endo","year":"2015","unstructured":"Endo I, Fukumoto S, Ozono K, et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr J. 2015;62(9):811\u20136.","journal-title":"Endocr J."},{"issue":"2","key":"905_CR5","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0031-3955(05)70485-5","volume":"44","author":"TO Carpenter","year":"1997","unstructured":"Carpenter TO. New perspectives on the biology and treatment of X-linked hypophosphatemic rickets. Pediatr Clin N Am. 1997;44(2):443\u201366.","journal-title":"Pediatr Clin N Am."},{"issue":"2","key":"905_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jcph.570","volume":"56","author":"X Zhang","year":"2016","unstructured":"Zhang X, Imel EA, Ruppe MD, et al. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J Clin Pharmacol. 2016;56(2):176\u201385.","journal-title":"J Clin Pharmacol."},{"issue":"4","key":"905_CR7","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/jcph.611","volume":"56","author":"X Zhang","year":"2016","unstructured":"Zhang X, Peyret T, Gosselin NH, et al. Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia. J Clin Pharmacol. 2016;56(4):429\u201338.","journal-title":"J Clin Pharmacol."},{"key":"905_CR8","unstructured":"European Medicines Agency. CRYSVITA (Burosumab): summary of product characteristics. 2018. \n                    http:\/\/ec.europa.eu\/\n                    \n                  . Accessed 4 Apr 2018."},{"key":"905_CR9","unstructured":"Ultragenyx Pharmaceutical Inc. Kyowa Kirin and Ultragenyx announce Crysvita\u00ae (burosumab) receives conditional marketing authorization in Europe for the treatment of X-linked hypophosphatemia in children. [media release]. 23 Feb 2018. \n                    http:\/\/ir.ultragenyx.com\/\n                    \n                  ."},{"key":"905_CR10","unstructured":"European Medicines Agency. New medicine for rare bone disease: Crysvita, a medicine for the treatment of X-linked hypophosphataemia, recommended for conditional approval. 2017. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 4 Apr 2018."},{"key":"905_CR11","unstructured":"European Medicines Agency. Human medicines highlights 2017. 2018. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 6 Apr 2018."},{"key":"905_CR12","unstructured":"US FDA. FDA approves first therapy for rare inherited form of rickets, x-linked hypophosphatemia. [media release]. 17 Apr 2018. \n                    http:\/\/www.fda.gov\/"},{"key":"905_CR13","unstructured":"Ultragenyx Pharmaceutical, Kyowa Hakko Kirin. Ultragenyx and Kyowa Hakko Kirin announce FDA acceptance and priority review designation of burosumabs biologics license application. [media release]. 10 Oct 2017. \n                    http:\/\/www.ultragenyx.com\n                    \n                  ."},{"key":"905_CR14","unstructured":"Ultragenyx Pharmaceutical. Ultragenyx granted EU orphan drug designation for KRN23 for the treatment of X-linked hypophosphatemia. [media release]. 30 Oct 2014. \n                    http:\/\/www.ultragenyx.com\n                    \n                  ."},{"key":"905_CR15","unstructured":"Ultragenyx Pharmaceutical, Inc. Ultragenyx announces collaboration with Kyowa Hakko Kirin to develop and commercialize phase 2-stage KRN23 for X-linked hypophosphatemia. [media release]. 3 Sep 2013. \n                    http:\/\/www.ultragenyx.com\n                    \n                  ."},{"key":"905_CR16","unstructured":"Ultragenyx Pharmaceutical Inc. Form 10-Q. 2017. \n                    http:\/\/ir.ultragenyx.com\/\n                    \n                  . Accessed 4 Apr 2018."},{"key":"905_CR17","unstructured":"Ultragenyx Pharmaceutical. Ultragenyx reports second quarter 2017 financial results and corporate update 2017. \n                    http:\/\/ir.ultragenyx.com\/\n                    \n                  . Accessed 4 Apr 2018."},{"key":"905_CR18","unstructured":"European Medicines Agency. CHMP assessment report: Crysvita (burosumab). 2017. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 4 Apr 2018."},{"key":"905_CR19","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1359\/jbmr.090509","volume":"24","author":"Y Aono","year":"2009","unstructured":"Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets\/osteomalacia. J Bone Miner Res. 2009;24:1879\u201388.","journal-title":"J Bone Miner Res."},{"issue":"4","key":"905_CR20","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1172\/JCI72829","volume":"124","author":"TO Carpenter","year":"2014","unstructured":"Carpenter TO, Imel EA, Ruppe MD, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124(4):1587\u201397.","journal-title":"J Clin Invest."},{"key":"905_CR21","unstructured":"Ultragenyx Pharmaceutical. Ultragenyx, Kyowa Hakko Kirin and Kyowa Kirin International announce positive 24-week data from adult phase 3 study of burosumab (KRN23) in X-linked hypophosphatemia. [media release]. 18 Apr 2017. \n                    http:\/\/www.ultragenyx.com\n                    \n                  ."},{"key":"905_CR22","unstructured":"Ultragenyx Pharmaceutical, Kyowa Kirin International, Kyowa Hakko Kirin. Ultragenyx and Kyowa Kirin announce positive 48-week data from adult phase 3 study of burosumab (KRN23) in X-linked hypophosphatemia. [media release]. 4 Dec 2017. \n                    http:\/\/www.ultragenyx.com\n                    \n                  ."},{"issue":"7","key":"905_CR23","doi-asserted-by":"publisher","first-page":"2565","DOI":"10.1210\/jc.2015-1551","volume":"100","author":"EA Imel","year":"2015","unstructured":"Imel EA, Zhang X, Ruppe MD, et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J Clin Endocrinol Metab. 2015;100(7):2565\u201373.","journal-title":"J Clin Endocrinol Metab."},{"key":"905_CR24","unstructured":"Ruppe M, Peacock M, Weber T, et al. Clinical and radiographic characteristics of adult X-linked hypophosphatemia (XLH) in a cohort of patients treated with KRN23, an antibody to FGF23 [abstract no. MO0319]. In: 38th Annual Meeting of the American Society for Bone and Mineral Research. 2016."},{"issue":"Suppl 1","key":"905_CR25","first-page":"S337","volume":"28","author":"T Carpenter","year":"2017","unstructured":"Carpenter T, Miller PD, Weber T, et al. Effects of KRN23, an anti-FGF23 antibody, in patients with tumor-induced osteomalacia or epidermal nevus syndrome-associated osteomalacia: Interim results from a phase 2 study [abstract no. P531]. Osteoporos Int. 2017;28(Suppl 1):S337\u20138.","journal-title":"Osteoporos Int."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0905-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0905-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0905-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,19]],"date-time":"2019-04-19T23:56:01Z","timestamp":1555718161000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0905-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0905-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"20 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the author on the basis of scientific completeness and accuracy. Yvette Lamb is a salaried employee of Adis\/Springer, is responsible for the article content and declares no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}